Fujifilm Medical Systems U.S.A. Inc.11.27.18
FUJIFILM Medical Systems U.S.A. Inc., a provider of diagnostic imaging and medical informatics solutions, has introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities.
“Fujifilm is a company of ‘firsts’ in diagnostic imaging. In 1936, we took our first steps in the development of X-ray film; and in 1983, we pioneered the first digitized radiography system in the world,” said Johann Fernando, Ph.D., chief operating officer of FUJIFILM Medical Systems U.S.A. Inc. “Once again we are innovating with the launch of the FCT Embrace, a solution that provides the most slices ever seen on an85cm bore system. Designed to improve radiation oncology care, this advanced solution boosts patient comfort and security by offering the widest tabletop currently available at 49cm, and accommodatingbariatric patients of up to 660lbs.”
The new, state-of-the-art FCT Embrace provides exceptional imaging capabilities on an easy-to-use, standardized platform for both radiology and oncology. Designed to improve accuracy throughout the entire oncology care cycle, the 85cm bore optimally matches the rotational arc of the linear accelerator—offering easy and precise positioning options for simulation and treatment planning. This unique solution allows oncology patients to be imaged in their optimal treatment position at the full clinical image quality afforded by 64 slice or greater systems for the first time; maintaining the accuracy requirements radiation oncology demands without compromising diagnostic image quality.
With over 80 years of medical imaging experience, Fujifilm’s expertise in brilliant image quality, low dose, and patient comfort is now available to the CT market for oncology, interventional CT and radiology.
FUJIFILM Medical Systems U.S.A. Inc. provides diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital X-ray systems, to the Synapse brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A. Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A. Inc. is headquartered in Stamford, Conn.
FUJIFILM Holdings Corporation in Tokyo, Japan, brings solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23 billion, at an exchange rate of 106 yen to the dollar. For more information, please visit: www.fujifilmholdings.com.
“Fujifilm is a company of ‘firsts’ in diagnostic imaging. In 1936, we took our first steps in the development of X-ray film; and in 1983, we pioneered the first digitized radiography system in the world,” said Johann Fernando, Ph.D., chief operating officer of FUJIFILM Medical Systems U.S.A. Inc. “Once again we are innovating with the launch of the FCT Embrace, a solution that provides the most slices ever seen on an85cm bore system. Designed to improve radiation oncology care, this advanced solution boosts patient comfort and security by offering the widest tabletop currently available at 49cm, and accommodatingbariatric patients of up to 660lbs.”
The new, state-of-the-art FCT Embrace provides exceptional imaging capabilities on an easy-to-use, standardized platform for both radiology and oncology. Designed to improve accuracy throughout the entire oncology care cycle, the 85cm bore optimally matches the rotational arc of the linear accelerator—offering easy and precise positioning options for simulation and treatment planning. This unique solution allows oncology patients to be imaged in their optimal treatment position at the full clinical image quality afforded by 64 slice or greater systems for the first time; maintaining the accuracy requirements radiation oncology demands without compromising diagnostic image quality.
With over 80 years of medical imaging experience, Fujifilm’s expertise in brilliant image quality, low dose, and patient comfort is now available to the CT market for oncology, interventional CT and radiology.
FUJIFILM Medical Systems U.S.A. Inc. provides diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital X-ray systems, to the Synapse brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A. Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A. Inc. is headquartered in Stamford, Conn.
FUJIFILM Holdings Corporation in Tokyo, Japan, brings solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23 billion, at an exchange rate of 106 yen to the dollar. For more information, please visit: www.fujifilmholdings.com.